Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price
NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […]
NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […]
